Benralizumab Reduces Exacerbations and Improves Lung Function in Patients From Republic of Korea With Severe, Uncontrolled Asthma: Subgroup Analysis of the SIROCCO Trial

Rationale In the Phase III SIROCCO RCT (Lancet. 2016;388:2115-270), benralizumab significantly improved asthma exacerbations, lung function, and symptoms for patients with severe, uncontrolled eosinophilic asthma. Conclusions Benralizumab meaningfully reduced asthma exacerbations, improved lung func...

Full description

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 2018-02, Vol.141 (2), p.AB14-AB14
Main Authors: Park, Hae-Sim, Lee, Sang Haak, Werkström, Viktoria, Wu, Yanping, Zangrilli, James, Gopalan, Gokul
Format: Article
Language:English
Subjects:
Asthma
Health risk assessment
Immunosuppressive agents
Lungs
Monoclonal antibodies
Respiratory function
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rationale In the Phase III SIROCCO RCT (Lancet. 2016;388:2115-270), benralizumab significantly improved asthma exacerbations, lung function, and symptoms for patients with severe, uncontrolled eosinophilic asthma. Conclusions Benralizumab meaningfully reduced asthma exacerbations, improved lung function, and was generally well tolerated in patients with severe, eosinophilic asthma from the Republic of Korea.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2017.12.043